Maze files for first biotech IPO of 2025, following $115M funding boost
Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D, forging a neuroscience spinoff and running into a dealmaking hurdle ...
View ArticleNovo expands pact with Flagship's Valo to include obesity, diabetes for $190M...
Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 potential drugs to 20. Wednesday morning's extended pact with the Flagship-founded...
View ArticleJasper reports more data in spontaneous hives from tiny study
Jasper Therapeutics continued building out the data for a drug designed to treat irritable skin conditions, though the latest results came from a small trial and without p-values. Researchers tested...
View ArticleLB Pharmaceuticals reveals Phase 2 schizophrenia data
A private startup looking to bring an old schizophrenia drug class to the US has released new Phase 2 data and aims to start a pivotal trial this year. On Wednesday, LB Pharmaceuticals said its ...
View ArticleUpdated: Galapagos to split into two companies, slash headcount as it eyes...
Galapagos is looking to have a fresh start after a rough few years. The Belgian biotech has outlined plans to branch off into two publicly traded businesses in a move that will see it terminate ...
View ArticleVir’s early T cell engager data offer first look at cancer pivot, stock jumps
Interim data on two T cell engagers that Vir Biotechnology licensed from Sanofi last year have begun to justify the biotech’s strategic shift into oncology. But the data are very early, and ...
View ArticleExclusive: GV-backed Prudentia launches with $7M to boost pharma dealmaking
Ahead of the busiest week for biopharma dealmaking at the annual JP Morgan Healthcare Conference, a new startup launched, believing its software will help prevent drugmakers from missing out on their...
View ArticleNovo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies
A Canadian biotech creating bioprinted tissue therapeutics for Type 1 diabetes, obesity and other endocrine and metabolic disorders has raised $115 million in a Series B. Vancouver-based Aspect...
View ArticleARCH, F-Prime and Mubadala pump $200M into former Denali programs
A new startup has emerged with $200 million and access to multiple preclinical drug candidates from neuroscience drugmaker Denali Therapeutics. On Wednesday morning, South San Francisco-based Tenvie...
View ArticleRoche's Chugai partners with Swiss ADC biotech Araris
Chugai, a Japanese pharma owned by Roche, is partnering with a small Swiss biotech to work on next-generation antibody-drug conjugates that deliver multiple cytotoxic molecules. Chugai will pay an...
View ArticleSolid Bio's former CEO launches new rare disease startup with €65M Series A
A new startup aiming to tackle rare diseases de-stealthed Wednesday morning with a CEO experienced in the space. Alesta Therapeutics took the wraps off its €65 million Series A ($67 million) that it...
View ArticleSana’s stock soars on new cell therapy data; UniQure’s $75M offering
Plus, news about Bioinvent, Alpha Cognition, Neumirna Therapeutics and Cassava Sciences: Sana Biotechnology finds life with new type 1 diabetes cell therapy data: The once high-flying biotech saw its...
View ArticleResilience cuts 120 employees at a former bluebird gene therapy site
National Resilience is laying off 120 staffers from its gene therapy facility in North Carolina, only a month after the San Diego-headquartered CDMO shrunk its headcount in Florida. This latest round...
View ArticleGene editing startup Scribe Therapeutics cuts staff by 20%
Scribe Therapeutics, a biotech co-founded by CRISPR pioneer Jennifer Doudna, is reducing its workforce by about 20%, the company confirmed to Endpoints News. CEO Ben Oakes told Endpoints by phone...
View ArticleTranscarent buys health navigation incumbent Accolade for $621M
Unicorn startup Transcarent has bought up a publicly traded rival as it looks to expand as a health navigation giant in one of the first health tech deals of the year. Accolade shareholders will...
View ArticleAstellas stops developing autologous cell therapy for lymphoma
Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma confirmed to Endpoints News on Wednesday. The pharma giant ended a
View ArticleAhead of adcomm, FDA discusses Seikagaku's mixed trial results for its lumbar...
Japan-based Seikagaku will face an FDA advisory committee on Friday, with the agency raising concerns ahead of the meeting regarding the efficacy of its condoliase injection for the treatment of...
View ArticlePfizer, GSK add risk of Guillain-Barré to RSV vaccine labels
Pfizer and GSK’s RSV vaccines have a new warning at the request of the FDA, relaying an increased risk of Guillain-Barré syndrome within the first 42 days post-vaccination. The agency said
View ArticleRevance weighs competing buyout offer amid push from original bidder
Revance Therapeutics said Wednesday it will have talks with Teoxane on its bid to take over Revance's company. But Crown Laboratories — the initial bidder — has made clear it won't wait much longer on...
View ArticleFirst-ever gene edit of infant boy leads to apparent cure
A baby boy born with a debilitating genetic disease will likely no longer require a liver transplant to stabilize his condition, thanks to a first-of-its-kind genetic medicine he got at 6 months of...
View Article